发明名称 | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof | ||
摘要 | The present invention relates to compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also inflammatory diseases. | ||
申请公布号 | US9062013(B2) | 申请公布日期 | 2015.06.23 |
申请号 | US201213983476 | 申请日期 | 2012.02.02 |
申请人 | Bionomics Limited | 发明人 | Harvey Andrew;Fluck Audrey;Giethlen Bruno;Paul Dharam;Schaeffer Laurent |
分类号 | C07D213/75;C07D231/40;C07D277/46;C07C311/46;C07C233/60;A61K31/44;A61K31/167;A61K31/36;A61K31/63;C07C233/59;C07C311/16;C07D317/46;C07D275/06;C07D209/46 | 主分类号 | C07D213/75 |
代理机构 | Honigman Miller Schwartz & Cohn LLP | 代理人 | Honigman Miller Schwartz & Cohn LLP ;Wootton, Esq. Thomas A.;O'Brien Jonathan P. |
主权项 | 1. A compound of formula (I) or a salt thereof: wherein R1 is selected from optionally substituted aryl, optionally substituted heteroaryl (excluding optionally substituted porphyrins), or optionally substituted heterocyclyl; R2 is selected from C1-C4 alkyl, C3-C5 alkenyl, F, Br, Cl, CN, or C1-C4 haloalkyl; R3 is selected from hydrogen, C1-C4 alkyl, C3-C5 alkenyl, F, Br, Cl, CN, or C1-C4 haloalkyl; orR2 and R3 together form C4-9 cycloalkyl or C4-9 cycloalkenyl;R4 is selected from optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted aryl;R5 is selected from hydrogen or optionally substituted alkyl;wherein when both R2 and R3 are Cl, R4 is an optionally substituted heteroaryl or optionally substituted heterocyclyl, andprovided that the following compounds are excluded: | ||
地址 | Thebarton AU |